

Part VI: Summary of the risk management plan

Summary of risk management plan for Bimatoprost

This is a summary of the risk management plan (RMP) for <INVENTED NAME>. The RMP details important risks of <INVENTED NAME>, how these risks can be minimised, and how more information will be obtained about <INVENTED NAME>'s risks and uncertainties (missing information).

<INVENTED NAME>'s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how <INVENTED NAME> should be used.

Important new concerns or changes to the current ones will be included in updates of <INVENTED NAME>'s RMP.

I. The medicine and what it is used for

<INVENTED NAME> eye drops, solution is indicated for reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).

It contains Bimatoprost as the active substance and it is given by ocular route of administration (eye drops).

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of <INVENTED NAME>, together with measures to minimise such risks and the proposed studies for -learning more about <INVENTED NAME>'s risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation measures*.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of <INVENTED NAME> is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of <INVENTED NAME> are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of <INVENTED NAME>. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Summary of safety concerns	
Important identified risks	<ul style="list-style-type: none"> - Iris pigmentation - Punctate keratitis - Acute asthma and asthmatic symptoms (Asthma, exacerbation of asthma, and Dyspnoea)
Important potential risks	<ul style="list-style-type: none"> - Reactivation of previous infective ocular disease - Choroidal effusion - Increase in intraocular pressure - Cardiovascular events (bradycardia, angina pectoris, and hypotension) - Off-label use (Cosmetic use for the purpose of stimulating eyelash growth)
Missing information	<ul style="list-style-type: none"> - Exposure in paediatric patients - Exposure in pregnancy and lactation

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan**II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation for <INVENTED NAME>.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for <INVENTED NAME>.

Part VII: Annexes

Table of contents

Annex 1 – EudraVigilance Interface

Annex 2–Tabulated summary of planned, ongoing, and completed pharmacovigilance study programme

Annex 3 - Protocols for proposed, on-going and completed studies in the pharmacovigilance plan

Annex 4 - Specific adverse drug reaction follow-up forms

Annex 5 - Protocols for proposed and on-going studies in RMP part IV

Annex 6 - Details of proposed additional risk minimisation activities (if applicable)

Annex 7 - Other supporting data (including referenced material)

Annex 8 – Summary of changes to the risk management plan over time